Please login to the form below

Not currently logged in
Email:
Password:

benign prostatic hyperplasia

This page shows the latest benign prostatic hyperplasia news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Sanofi’s all-oral sleeping sickness drug

CHMP backs Sanofi’s all-oral sleeping sickness drug

Italy’s Recordati also got a positive opinion for Silodosin Recordati (siloosin) a generic of its own Urorec drug used to treat benign prostatic hyperplasia (BPH).

Latest news

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Interview: Giovanni Recordati Interview: Giovanni Recordati

    The company also has long expertise in urology. “We are currently rolling out a new drug for the treatment of benign prostatic hyperplasia and will soon be starting the last phase

  • Call to action for BPH

    Campaign:ProState of the Nation. Timescale:February to October 2009. ProState of the Nation is an evidence-based report, bringing the issues of under-management and under-treatment of Benign Prostatic ... Benign Prostatic Hyperplasia (BPH) is a condition

  • Interview: Jorge Gallardo, Almirall Interview: Jorge Gallardo, Almirall

    The year's sales evolution has benefited from the launches of new products Silodyx (for benign prostatic hyperplasia, licence from Recordati)  and Conbriza  (for osteoporosis, in co-promotion with Pfizer) in

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....